Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Peter A. Kaufman; Hans Wildiers; Gilles Freyer; Margaret Kemeny; Anthony Gonçalves; Guy Jerusalem; Alison Stopeck; Nandagopal Vrindavanam; Florence Dalenc; Nuwan Nanayakkara; Benjamin Wu; Cheryl A. Pickett

doi:10.1016/j.clbc.2018.09.012

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Peter A. Kaufman
, Hans Wildiers
, Gilles Freyer
, Margaret Kemeny
, Anthony Gonçalves
, Guy Jerusalem
, Alison Stopeck
, Nandagopal Vrindavanam
, Florence Dalenc
, Nuwan Nanayakkara
, Benjamin Wu
, Cheryl A. Pickett

Cancer Center

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

Original language	English (US)
Pages (from-to)	47-57
Number of pages	11
Journal	Clinical Breast Cancer
Volume	19
Issue number	1
DOIs	https://doi.org/10.1016/j.clbc.2018.09.012
State	Published - Feb 2019

Keywords

AMG 386
Angiogenesis
Angiopoietin
HER2 positive

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.clbc.2018.09.012

Cite this

Kaufman, P. A., Wildiers, H., Freyer, G., Kemeny, M., Gonçalves, A., Jerusalem, G., Stopeck, A., Vrindavanam, N., Dalenc, F., Nanayakkara, N., Wu, B., & Pickett, C. A. (2019). Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 19(1), 47-57. https://doi.org/10.1016/j.clbc.2018.09.012

Kaufman, PA, Wildiers, H, Freyer, G, Kemeny, M, Gonçalves, A, Jerusalem, G, Stopeck, A, Vrindavanam, N, Dalenc, F, Nanayakkara, N, Wu, B & Pickett, CA 2019, 'Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer', Clinical Breast Cancer, vol. 19, no. 1, pp. 47-57. https://doi.org/10.1016/j.clbc.2018.09.012

@article{63ebd5b98fa0477bb293094f3327cccc,

title = "Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer",

abstract = "Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.",

keywords = "AMG 386, Angiogenesis, Angiopoietin, HER2 positive",

author = "Kaufman, \{Peter A.\} and Hans Wildiers and Gilles Freyer and Margaret Kemeny and Anthony Gon{\c c}alves and Guy Jerusalem and Alison Stopeck and Nandagopal Vrindavanam and Florence Dalenc and Nuwan Nanayakkara and Benjamin Wu and Pickett, \{Cheryl A.\}",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2019",

month = feb,

doi = "10.1016/j.clbc.2018.09.012",

language = "English (US)",

volume = "19",

pages = "47--57",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

AU - Kaufman, Peter A.

AU - Wildiers, Hans

AU - Freyer, Gilles

AU - Kemeny, Margaret

AU - Gonçalves, Anthony

AU - Jerusalem, Guy

AU - Stopeck, Alison

AU - Vrindavanam, Nandagopal

AU - Dalenc, Florence

AU - Nanayakkara, Nuwan

AU - Wu, Benjamin

AU - Pickett, Cheryl A.

PY - 2019/2

Y1 - 2019/2

N2 - Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

AB - Given the potential interactions between human epidermal growth factor receptor 2 (HER2) signaling and angiogenesis, we investigated the angiopoietin (Ang) 1/Ang2 inhibitor trebananib plus trastuzumab and paclitaxel in HER2-positive breast cancer. Forty women received trebananib (10 or 30 mg/kg) plus trastuzumab and paclitaxel. The combination demonstrated acceptable toxicity and antitumor response in HER2-positive locally recurrent/metastatic breast cancer.

KW - AMG 386

KW - Angiogenesis

KW - Angiopoietin

KW - HER2 positive

UR - https://www.scopus.com/pages/publications/85056336575

UR - https://www.scopus.com/pages/publications/85056336575#tab=citedBy

U2 - 10.1016/j.clbc.2018.09.012

DO - 10.1016/j.clbc.2018.09.012

M3 - Article

C2 - 30420181

AN - SCOPUS:85056336575

SN - 1526-8209

VL - 19

SP - 47

EP - 57

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 1

ER -

Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this